Tech Company Financing Transactions

Actio Biosciences Funding Round

On 6/19/2025, Actio Biosciences raised $66 million in Series B investment from Deerfield Management Company, Regeneron Pharmaceuticals and Canaan Partners.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

9310 Athena Circle 100
San Diego, CA 92037
USA

Phone

Undisclosed

Website

www.actiobiosciences.com

Email Address

Undisclosed

Overview

Actio was founded by leaders in genetics and drug development to push the boundaries of how we translate genetic insights into new medicines. Actio is more than a precision medicine company -- we have a bold vision to take learnings in how we pinpoint targets and develop drugs for homogenous rare disease populations and leverage those learnings to identify underlying biology in heterogenous common disease populations. Through our unique approach, we aim to bring meaningful new therapeutics from one to many.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

        

Chief Executive Officer

David Goldstein

        

Chief Scientific Officer

David Breckenridge

        

Co-Founder

John McHutchison

        

Browse more venture capital transactions:

Prev: 6/18/2025: Materna Medical venture capital transaction
Next: 6/19/2025: PointCaré venture capital transaction

Share this article

News on VC Transactions

We report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary